Physician profile
Chasen Halcomb
NPI 1689184616
$2,377.26
in general payments reported to CMS, 2019-2025
25 companies · $402 in 2025
The $402 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.71 · 2022: $258 · 2023: $1,135 · 2024: $557 · 2025: $402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,094.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,094.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $419.32 | 2023-2024 | Dupixent, Libtayo |
| Abbvie INC. | $297.03 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $233.86 | 2022-2025 | Blu-U, Odomzo |
| Revance Therapeutics, INC. | $195.68 | 2024 | Daxi, Daxxify |
| Novartis Pharmaceuticals Corporation | $155.02 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $113.87 | 2023 | Tremfya |
| Amgen INC. | $105.84 | 2022-2025 | Otezla, Otezla |
| Horizon Therapeutics Plc | $101.17 | 2023 | Krystexxa |
| Merz North America, INC. | $92.75 | 2023 | Xeomin |
| E.R. Squibb & Sons, L.L.C. | $89.00 | 2023-2025 | Sotyktu |
| Pfizer INC. | $84.07 | 2022-2023 | |
| Galderma Laboratories, L.P. | $59.81 | 2023-2025 | Nemluvio |
| Ucb, INC. | $54.54 | 2024 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $51.97 | 2025 | Tremfya, Simponi, Stelara |
| Arcutis Biotherapeutics, INC. | $51.73 | 2024 | Zoryve |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $40.87 | 2022-2023 | Poteligeo |
| Merck Sharp & Dohme LLC | $37.80 | 2023 | Keytruda |
| Incyte Corporation | $36.82 | 2023-2025 | Opzelura |
| Mimedx Group, INC. | $35.13 | 2025 | |
| Dermavant Sciences, INC. | $30.60 | 2023 | Vtama |
| Lilly USA, LLC | $24.68 | 2024 | Ebglyss |
| Biofrontera INC. | $20.76 | 2025 | |
| Genzyme Corporation | $15.82 | 2024 | |
| Leo Pharma INC. | $15.17 | 2023 | Adbry |
| Paratek Pharmaceuticals, INC. | $13.95 | 2023 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chasen Halcomb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.